NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech

Shares in NeuroMetrix (NSDQ:NURO) soared this morning after the company announced it would partner with GlaxoSmithKline (NYSE:GSK) to expand development of NeuroMetrix’s Quell wearable pain-relief device.
According to the terms of the deal, GSK’s consumer healthcare business will have exclusive rights to the Quell system for markets outside of the U.S., while NeuroMetrix will retain ownership of the device within the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech appeared first on MassDevice.

Source: Mass Device - January 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: mHealth (Mobile Health) Pain Management Research & Development Wall Street Beat GlaxoSmithKline plc Neurometrix Source Type: news